人参皂苷 RG5
中文名称 | 人参皂苷 RG5 |
---|---|
中文同义词 | 人参皂苷 RG5;人参皂苷RG5, 来源于人参;人参皂甙 RG5?, >99%;人参皂甙 RG5;人参皂苷RG5标准品;人参皂苷RG5对照品 |
英文名称 | Ginsenoside-Rg5 |
英文同义词 | Ginsenoside-Rg5;(3beta,12beta,20E)-12-Hydroxydammara-20(22),24-dien-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside;Ginsenoside Rg5, 98%, from Panax ginseng C. A. Mey.;Ginsenoside Rg5, >99%;b-D-Glucopyranoside, (3b,12b,20E)-12-hydroxydammara-20(22),24-dien-3-yl 2-O-b-D-glucopyranosyl-;β-D-Glucopyranoside, (3β,12β,20E)-12-hydroxydammara-20(22),24-dien-3-yl 2-O-β-D-glucopyranosyl-;(8ξ,9ξ,12α,13ξ,14β,17β)-12-Hydroxy-4,4,7,10,14-pentamethyl-17-[(2 E)-6-methyl-2,5-heptadien-2-yl]gonan-3-yl 2-O-β-D-glucopyranosyl- β-D-glucopyranoside;GinsenosideRrg5 |
CAS号 | 186763-78-0 |
分子式 | C42H70O12 |
分子量 | 767 |
EINECS号 | |
植物来源 | 人参 |
相关类别 | 对照品,标准品;标准品;对照品;中药对照品;植物提取物;标准品-对照品;分析试剂标准品;对照品-中药对照品;标准品 -中药标准品 |
Mol文件 | 186763-78-0.mol |
结构式 |
人参皂苷 RG5 性质
沸点 | 855.6±65.0 °C(Predicted) |
---|---|
密度 | 1.28±0.1 g/cm3 (20 ºC 760 Torr) |
储存条件 | 2-8°C |
溶解度 | 溶于DMSO;微溶于甲醇; |
形态 | 粉末 |
酸度系数(pKa) | 12.85±0.70(Predicted) |
颜色 | 白色 |
水溶解性 | insoluble in water |
InChIKey | NJUXRKMKOFXMRX-SELNEYDKSA-N |
人参皂苷 RG5提取自蒸参,可用于含量测定/鉴定/药理实验等。
Ginsenoside Rg5 是红参的主要成分。Ginsenoside Rg5 阻断 IGF-1 与其受体的结合,IC50 约为90 nM。Ginsenoside Rg5 还通过抑制 NF-κB p65 的 DNA 结合活性来抑制 COX-2 的 mRNA 表达。
p65
|
COX-2
|
IGF-1R 90 nM (IC 50 ) |
Ginsenoside Rg5 plays a novel role as an IGF-1R agonist. Ginsenoside Rg5 binds to IGF-1R with an IC 50 value of ~90 and its angiogenic activity is inhibited by IGF-1R knockdown. To investigate the possible interaction of Ginsenoside Rg5 with IGF-1R, a docking analysis is performed. Docking results show that Ginsenoside Rg5 binds strongly at two sites, A and B, with K d values of 20 and 27 nM, respectively, to the cysteine-rich domain of IGF-1R. Pretreatment with Rg5 blocks the binding of radiolabeled IGF-1 to HUVECs with an IC 50 value of ~90 μM, which is greater than an IC 50 value of ~1.4 nM for unlabeled IGF-1. The results from MTT assay show that MCF-7 cell proliferation is inhibited by Ginsenoside Rg5 treatment for 24, 48 and 72 h in a dose-dependent manner. Ginsenoside Rg5 at different concentrations (0, 25, 50 and 100 μM), induce cell cycle arrest in G0/G1 phase through regulation of cell cycle-related proteins in MCF-7 cells.
Ginsenoside Rg5 inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65 in lipopolysaccharides (LPS)-stimulated BV2 microglial cells. Rg5 pretreated group mice show declined expression of NF-κB p65 and COX-2. In the group treated with low dose of Ginsenoside Rg5 (10 mg/kg), there is remarkable tubular damage and infiltration of inflammatory cells. However, at the higher dose of Ginsenoside Rg5 (20 mg/kg), tubules markedly appeare histologically normal and no inflammation and cast formation is observed in kidney tissues.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-N0908 | 人参皂苷 RG5 Ginsenoside Rg5 | 186763-78-0 | 5mg | 2800元 |
2024/04/30 | HY-N0908 | 人参皂苷 RG5 Ginsenoside Rg5 | 186763-78-0 | 10mM * 1mLin DMSO | 3797元 |